These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37790608)

  • 1. Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease.
    Lebedeva S; Margaryan A; Smolyarchuk E; Nedorubov A; Materenchuk M; Tonevitsky A; Mutig K
    Front Endocrinol (Lausanne); 2023; 14():1176199. PubMed ID: 37790608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a functional V
    Hus-Citharel A; Bouby N; Corbani M; Mion J; Mendre C; Darusi J; Tomboly C; Trueba M; Serradeil-Le Gal C; Llorens-Cortes C; Guillon G
    Am J Physiol Renal Physiol; 2021 Sep; 321(3):F305-F321. PubMed ID: 34282956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic and renal sympathetic responses to V1b vasopressin receptor activation within the paraventricular nucleus.
    El-Werfali W; Toomasian C; Maliszewska-Scislo M; Li C; Rossi NF
    Exp Physiol; 2015 Apr; 100(5):553-65. PubMed ID: 25605313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.
    Bankir L
    Cardiovasc Res; 2001 Aug; 51(3):372-90. PubMed ID: 11476728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin and vasopressin receptors in brain edema.
    Zeynalov E; Jones SM; Elliott JP
    Vitam Horm; 2020; 113():291-312. PubMed ID: 32138953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarities between hamster pancreatic islet beta (HIT) cell vasopressin receptors and V1b receptors.
    Richardson SB; Laya T; VanOoy M
    J Endocrinol; 1995 Oct; 147(1):59-65. PubMed ID: 7490538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin and diabetic nephropathy.
    Roussel R; Velho G; Bankir L
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):311-318. PubMed ID: 28403013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway.
    Volpi S; Liu Y; Aguilera G
    J Mol Endocrinol; 2006 Jun; 36(3):581-90. PubMed ID: 16720725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V
    Taveau C; Chollet C; Bichet DG; Velho G; Guillon G; Corbani M; Roussel R; Bankir L; Melander O; Bouby N
    Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E127-E135. PubMed ID: 27998960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin V1a and V1b receptors: from molecules to physiological systems.
    Koshimizu TA; Nakamura K; Egashira N; Hiroyama M; Nonoguchi H; Tanoue A
    Physiol Rev; 2012 Oct; 92(4):1813-64. PubMed ID: 23073632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
    Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M
    Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin.
    Hernando F; Schoots O; Lolait SJ; Burbach JP
    Endocrinology; 2001 Apr; 142(4):1659-68. PubMed ID: 11250948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
    J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).
    Ślusarz MJ
    Expert Opin Ther Pat; 2015 Jun; 25(6):711-22. PubMed ID: 25776143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin and Diabetic Kidney Disease.
    El Boustany R
    Ann Nutr Metab; 2018; 72 Suppl 2():17-20. PubMed ID: 29925069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat.
    Rabadan-Diehl C; Lolait SJ; Aguilera G
    J Neuroendocrinol; 1995 Dec; 7(12):903-10. PubMed ID: 8745267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin: a novel target for the prevention and retardation of kidney disease?
    Bankir L; Bouby N; Ritz E
    Nat Rev Nephrol; 2013 Apr; 9(4):223-39. PubMed ID: 23438973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors.
    Young SF; Griffante C; Aguilera G
    Cell Mol Neurobiol; 2007 Jun; 27(4):439-61. PubMed ID: 17318384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.